{"id":18658,"date":"2022-02-16T08:04:47","date_gmt":"2022-02-16T16:04:47","guid":{"rendered":"https:\/\/marketdepth.com\/?p=18658"},"modified":"2022-02-16T08:04:49","modified_gmt":"2022-02-16T16:04:49","slug":"hookipa-and-gilead-announced-amended-collaboration-to-develop-immunotherapies-against-hiv","status":"publish","type":"post","link":"https:\/\/marketdepth.com\/hookipa-and-gilead-announced-amended-collaboration-to-develop-immunotherapies-against-hiv\/","title":{"rendered":"HOOKIPA and Gilead Announced Amended Collaboration to Develop Immunotherapies Against HIV"},"content":{"rendered":"\n<p>HOOKIPA Pharma Inc. (NASDAQ: HOOK) announced it has entered into an amended and restated collaboration and license agreement with Gilead Sciences, Inc. (NASDAQ: GILD) to advance the development of a novel arenaviral immunotherapy as a component of a potential functional curative regimen for human immunodeficiency virus (HIV).<\/p>\n\n\n\n<h5 class=\"wp-block-heading\">Platform for Immunotherapies<\/h5>\n\n\n\n<p>In April 2018, Gilead\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=m477aD_II1hOfM-sQE2jNQB2Vuo0cT4IeIx4dKGOu8lI5OmygiJxdT3953h7UwY4QlhhV2AFuKxxtfav-PwkMHRI-dlUoS5Xi1jyZFkvjYq2ljj8BmTP36fRYtlMWmcuypaLP_KPL1jNNW4kUUWspDQNAbkp2FDXIZl-d-AyXGoZUN2CBMX4CNrm9SMrF66UNLdgkkWYqOzEy0WgEsRdulZieqrQNsGQdD0VVunxOPg=\">licensed exclusive rights<\/a>\u00a0to HOOKIPA\u2019s versatile arenaviral platform to develop immunotherapies for HIV and hepatitis B virus (HBV). Under those terms, the companies agreed to collaborate through a joint research phase, after which time Gilead had rights for further development. Under the amended and restated agreement, HOOKIPA is responsible for advancing the HIV program through the completion of a Phase 1b clinical trial, with funding from Gilead via an upfront payment and equity purchases. At the completion of the Phase 1b trial, Gilead has the exclusive right to assume further development of the program. The HBV portion of the agreement remains unchanged.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-style-large\"><p>\u201cWe are pleased to enter into this amended agreement with Gilead which includes provisions that we believe benefit both parties, and we hope ultimately the HIV community. Gilead is helping to advance our novel arenaviral platform technology, which has the potential to complement Gilead\u2019s overall research strategies for cures of HIV and HBV.\u201d<\/p><cite>Joern Aldag, Chief Executive Officer at HOOKIPA<\/cite><\/blockquote>\n","protected":false},"excerpt":{"rendered":"HOOKIPA Pharma Inc. (NASDAQ: HOOK) announced it has entered into an amended and restated collaboration and license agreement with Gilead Sciences, Inc. (NASDAQ: GILD) to advance the development of a novel arenaviral immunotherapy as a component of a potential functional curative regimen for human immunodeficiency virus (HIV). Platform for Immunotherapies In April 2018, Gilead\u00a0licensed exclusive&#8230; <a class=\"view-article\" href=\"https:\/\/marketdepth.com\/hookipa-and-gilead-announced-amended-collaboration-to-develop-immunotherapies-against-hiv\/\">View Article<\/a>","protected":false},"author":3,"featured_media":18385,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":0,"footnotes":""},"categories":[9,17,8,11,16],"tags":[],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.0 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>HOOKIPA and Gilead Announced Amended Collaboration to Develop Immunotherapies Against HIV - MarketDepth<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/marketdepth.com\/hookipa-and-gilead-announced-amended-collaboration-to-develop-immunotherapies-against-hiv\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"HOOKIPA and Gilead Announced Amended Collaboration to Develop Immunotherapies Against HIV - MarketDepth\" \/>\n<meta property=\"og:description\" content=\"HOOKIPA Pharma Inc. (NASDAQ: HOOK) announced it has entered into an amended and restated collaboration and license agreement with Gilead Sciences, Inc. (NASDAQ: GILD) to advance the development of a novel arenaviral immunotherapy as a component of a potential functional curative regimen for human immunodeficiency virus (HIV). Platform for Immunotherapies In April 2018, Gilead\u00a0licensed exclusive... View Article\" \/>\n<meta property=\"og:url\" content=\"https:\/\/marketdepth.com\/hookipa-and-gilead-announced-amended-collaboration-to-develop-immunotherapies-against-hiv\/\" \/>\n<meta property=\"og:site_name\" content=\"MarketDepth\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/marketdepthnews\" \/>\n<meta property=\"article:published_time\" content=\"2022-02-16T16:04:47+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-02-16T16:04:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/marketdepth.com\/wp-content\/uploads\/2022\/01\/Medical-Microscope-research.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1280\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"MarketDepth\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@MarketDepthNews\" \/>\n<meta name=\"twitter:site\" content=\"@MarketDepthNews\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"MarketDepth\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/marketdepth.com\/hookipa-and-gilead-announced-amended-collaboration-to-develop-immunotherapies-against-hiv\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/marketdepth.com\/hookipa-and-gilead-announced-amended-collaboration-to-develop-immunotherapies-against-hiv\/\"},\"author\":{\"name\":\"MarketDepth\",\"@id\":\"https:\/\/marketdepth.com\/#\/schema\/person\/1c07fd6f269e57bf07013b63d7245f69\"},\"headline\":\"HOOKIPA and Gilead Announced Amended Collaboration to Develop Immunotherapies Against HIV\",\"datePublished\":\"2022-02-16T16:04:47+00:00\",\"dateModified\":\"2022-02-16T16:04:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/marketdepth.com\/hookipa-and-gilead-announced-amended-collaboration-to-develop-immunotherapies-against-hiv\/\"},\"wordCount\":228,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/marketdepth.com\/#organization\"},\"articleSection\":[\"Biotechnology\",\"Headlines\",\"Healthcare\",\"Investing\",\"What's Hot\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/marketdepth.com\/hookipa-and-gilead-announced-amended-collaboration-to-develop-immunotherapies-against-hiv\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/marketdepth.com\/hookipa-and-gilead-announced-amended-collaboration-to-develop-immunotherapies-against-hiv\/\",\"url\":\"https:\/\/marketdepth.com\/hookipa-and-gilead-announced-amended-collaboration-to-develop-immunotherapies-against-hiv\/\",\"name\":\"HOOKIPA and Gilead Announced Amended Collaboration to Develop Immunotherapies Against HIV - MarketDepth\",\"isPartOf\":{\"@id\":\"https:\/\/marketdepth.com\/#website\"},\"datePublished\":\"2022-02-16T16:04:47+00:00\",\"dateModified\":\"2022-02-16T16:04:49+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/marketdepth.com\/hookipa-and-gilead-announced-amended-collaboration-to-develop-immunotherapies-against-hiv\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/marketdepth.com\/hookipa-and-gilead-announced-amended-collaboration-to-develop-immunotherapies-against-hiv\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/marketdepth.com\/hookipa-and-gilead-announced-amended-collaboration-to-develop-immunotherapies-against-hiv\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/marketdepth.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"HOOKIPA and Gilead Announced Amended Collaboration to Develop Immunotherapies Against HIV\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/marketdepth.com\/#website\",\"url\":\"https:\/\/marketdepth.com\/\",\"name\":\"MarketDepth\",\"description\":\"Stock Market News &amp; Headlines\",\"publisher\":{\"@id\":\"https:\/\/marketdepth.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/marketdepth.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/marketdepth.com\/#organization\",\"name\":\"MarketDepth\",\"url\":\"https:\/\/marketdepth.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/marketdepth.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/marketdepth.com\/wp-content\/uploads\/2021\/05\/MarketDepth-Placeholder-1.jpg\",\"contentUrl\":\"https:\/\/marketdepth.com\/wp-content\/uploads\/2021\/05\/MarketDepth-Placeholder-1.jpg\",\"width\":1500,\"height\":1000,\"caption\":\"MarketDepth\"},\"image\":{\"@id\":\"https:\/\/marketdepth.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/marketdepthnews\",\"https:\/\/twitter.com\/MarketDepthNews\",\"https:\/\/www.instagram.com\/marketdepth\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/marketdepth.com\/#\/schema\/person\/1c07fd6f269e57bf07013b63d7245f69\",\"name\":\"MarketDepth\",\"url\":\"https:\/\/marketdepth.com\/author\/3\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"HOOKIPA and Gilead Announced Amended Collaboration to Develop Immunotherapies Against HIV - MarketDepth","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/marketdepth.com\/hookipa-and-gilead-announced-amended-collaboration-to-develop-immunotherapies-against-hiv\/","og_locale":"en_US","og_type":"article","og_title":"HOOKIPA and Gilead Announced Amended Collaboration to Develop Immunotherapies Against HIV - MarketDepth","og_description":"HOOKIPA Pharma Inc. (NASDAQ: HOOK) announced it has entered into an amended and restated collaboration and license agreement with Gilead Sciences, Inc. (NASDAQ: GILD) to advance the development of a novel arenaviral immunotherapy as a component of a potential functional curative regimen for human immunodeficiency virus (HIV). Platform for Immunotherapies In April 2018, Gilead\u00a0licensed exclusive... View Article","og_url":"https:\/\/marketdepth.com\/hookipa-and-gilead-announced-amended-collaboration-to-develop-immunotherapies-against-hiv\/","og_site_name":"MarketDepth","article_publisher":"https:\/\/www.facebook.com\/marketdepthnews","article_published_time":"2022-02-16T16:04:47+00:00","article_modified_time":"2022-02-16T16:04:49+00:00","og_image":[{"width":1920,"height":1280,"url":"https:\/\/marketdepth.com\/wp-content\/uploads\/2022\/01\/Medical-Microscope-research.jpg","type":"image\/jpeg"}],"author":"MarketDepth","twitter_card":"summary_large_image","twitter_creator":"@MarketDepthNews","twitter_site":"@MarketDepthNews","twitter_misc":{"Written by":"MarketDepth","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/marketdepth.com\/hookipa-and-gilead-announced-amended-collaboration-to-develop-immunotherapies-against-hiv\/#article","isPartOf":{"@id":"https:\/\/marketdepth.com\/hookipa-and-gilead-announced-amended-collaboration-to-develop-immunotherapies-against-hiv\/"},"author":{"name":"MarketDepth","@id":"https:\/\/marketdepth.com\/#\/schema\/person\/1c07fd6f269e57bf07013b63d7245f69"},"headline":"HOOKIPA and Gilead Announced Amended Collaboration to Develop Immunotherapies Against HIV","datePublished":"2022-02-16T16:04:47+00:00","dateModified":"2022-02-16T16:04:49+00:00","mainEntityOfPage":{"@id":"https:\/\/marketdepth.com\/hookipa-and-gilead-announced-amended-collaboration-to-develop-immunotherapies-against-hiv\/"},"wordCount":228,"commentCount":0,"publisher":{"@id":"https:\/\/marketdepth.com\/#organization"},"articleSection":["Biotechnology","Headlines","Healthcare","Investing","What's Hot"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/marketdepth.com\/hookipa-and-gilead-announced-amended-collaboration-to-develop-immunotherapies-against-hiv\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/marketdepth.com\/hookipa-and-gilead-announced-amended-collaboration-to-develop-immunotherapies-against-hiv\/","url":"https:\/\/marketdepth.com\/hookipa-and-gilead-announced-amended-collaboration-to-develop-immunotherapies-against-hiv\/","name":"HOOKIPA and Gilead Announced Amended Collaboration to Develop Immunotherapies Against HIV - MarketDepth","isPartOf":{"@id":"https:\/\/marketdepth.com\/#website"},"datePublished":"2022-02-16T16:04:47+00:00","dateModified":"2022-02-16T16:04:49+00:00","breadcrumb":{"@id":"https:\/\/marketdepth.com\/hookipa-and-gilead-announced-amended-collaboration-to-develop-immunotherapies-against-hiv\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/marketdepth.com\/hookipa-and-gilead-announced-amended-collaboration-to-develop-immunotherapies-against-hiv\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/marketdepth.com\/hookipa-and-gilead-announced-amended-collaboration-to-develop-immunotherapies-against-hiv\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/marketdepth.com\/"},{"@type":"ListItem","position":2,"name":"HOOKIPA and Gilead Announced Amended Collaboration to Develop Immunotherapies Against HIV"}]},{"@type":"WebSite","@id":"https:\/\/marketdepth.com\/#website","url":"https:\/\/marketdepth.com\/","name":"MarketDepth","description":"Stock Market News &amp; Headlines","publisher":{"@id":"https:\/\/marketdepth.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/marketdepth.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/marketdepth.com\/#organization","name":"MarketDepth","url":"https:\/\/marketdepth.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/marketdepth.com\/#\/schema\/logo\/image\/","url":"https:\/\/marketdepth.com\/wp-content\/uploads\/2021\/05\/MarketDepth-Placeholder-1.jpg","contentUrl":"https:\/\/marketdepth.com\/wp-content\/uploads\/2021\/05\/MarketDepth-Placeholder-1.jpg","width":1500,"height":1000,"caption":"MarketDepth"},"image":{"@id":"https:\/\/marketdepth.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/marketdepthnews","https:\/\/twitter.com\/MarketDepthNews","https:\/\/www.instagram.com\/marketdepth\/"]},{"@type":"Person","@id":"https:\/\/marketdepth.com\/#\/schema\/person\/1c07fd6f269e57bf07013b63d7245f69","name":"MarketDepth","url":"https:\/\/marketdepth.com\/author\/3\/"}]}},"_links":{"self":[{"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/posts\/18658"}],"collection":[{"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/comments?post=18658"}],"version-history":[{"count":1,"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/posts\/18658\/revisions"}],"predecessor-version":[{"id":18659,"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/posts\/18658\/revisions\/18659"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/media\/18385"}],"wp:attachment":[{"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/media?parent=18658"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/categories?post=18658"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/marketdepth.com\/wp-json\/wp\/v2\/tags?post=18658"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}